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Abstract
Background: Pyrazinamide (PZA) is an important first-line drug in multidrug-resistant tuberculosis (MDRTB)
treatment. However, the unreliable results obtained from traditional susceptibility testing limits its usefulness in
clinical settings. The detection of pncA gene mutations is a potential surrogate of PZA susceptibility testing,
especially in MDRTB isolates. The impact of genotypes of M. tuberculosis in pncA gene mutations also remains to
be clarified.
Methods: MDRTB isolates were collected from six hospitals in Taiwan from January 2007 to December 2009. pncA
gene sequencing, pyrazinamidase activity testing, and spoligotyping were performed on all of the isolates. PZA
susceptibility was determined by the BACTEC MGIT 960 PZA method. The sensitivity and specificity of pncA gene
analysis were estimated based on the results of PZA susceptibility testing.
Results: A total of 66 MDRTB isolates, including 37 Beijing and 29 non-Beijing strains, were included for analysis.
Among these isolates, 36 (54.5%) were PZA-resistant and 30 (45.5%) were PZA-susceptible. The PZA-resistant
isolates were more likely to have concomitant resistance to ethambutol and streptomycin. Thirty-seven mutation
types out of 30 isolates were identified in the pncA gene, and most of them were point mutations. The sensitivities
of pncA gene sequencing for PZA susceptibility in overall isolates, Beijing and non-Beijing strains were 80.6%,
76.2%, and 86.7% respectively, and the specificities were 96.7%, 93.8%, and 100% respectively.
Conclusions: More than half of the MDRTB isolates in this study are PZA-resistant. Analysis of pncA gene mutations
helped to identify PZA-susceptible MDRTB isolates, especially in non-Beijing strains.
Background
Despite the recent advances in management, tuberculo-
sis (TB) remains a leading cause of mortality and mor-
bidity worldwide. The emergence of multidrug-resistant
tuberculosis (MDRTB) further constitutes a serious
threat to the control of TB. In Taiwan, the incidence of
TB was 63.2/100,000 population in 2007 and 62.0/
100,000 population in 2008 (1). The Taiwan drug resis-
tance surveillance program revealed that the combined
drug resistance rates in 2005 were 10.1% for isoniazid
(INH), 6.2% for rifampicin (RIF), and 4.0% for MDRTB
(2). Among the various genotypes of Mycobacterium
tuberculosis (MTB), the Beijing genotype is the domi-
nant strain in Taiwan (3, 4).
Pyrazinamide (PZA) is an important first-line anti-
t u b e r c u l o s i s( a n t i - T B )d r u gt h a ti su s e di ns h o r t - c o u r s e
chemotherapy and is one of the cornerstone drugs in
the treatment of MDRTB (5). Through pyrazinamidase
(PZase) which is constitutively expressed in Mycobacter-
ium tuberculosis (MTB), PZA is hydrolyzed to toxic pyr-
azinoic acid (POA) intracellularly (6, 7). Although the
exact mechanism is unknown, it has been postulated
that POA exerts an inhibitory effect on cellular metabo-
lism in acidic conditions (8-10). The PZase enzyme is
encoded by the pncA gene (11). Mutations in the pncA
gene may cause a reduction in PZase activity which may
be the major mechanism of PZA resistance in MTB (12,
13). Previous reports have well characterized the muta-
tions of the pncA gene in PZA-resistant MTB isolates,
however the correlation varies between different geogra-
phical areas (14-17). A great diversity of pncA gene
mutations has also been described, including missense
mutations, one or more base insertions or deletions, and
* Correspondence: jyfeng@vghtpe.gov.tw; wjsu@vghtpe.gov.tw
1Department of Chest Medicine, Taipei Veterans General Hospital, Shih-Pai
Rd., Taipei 112, Taiwan, ROC
Full list of author information is available at the end of the article
Chiu et al. BMC Infectious Diseases 2011, 11:240
http://www.biomedcentral.com/1471-2334/11/240
© 2011 Chiu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.complete deletion (12, 13, 18). Meanwhile, a substantial
proportion of resistant isolates have been found to have
intact PZase activity without pncA gene mutations, sug-
gesting an alternative mechanism of PZA resistance.
Due to the inhibitory effect of low pH on in vitro
growth of MTB, conventional PZA drug susceptibility
testing on a solid medium is of limited value and not
routinely done in many areas (19). Considering the
unique bactericidal effect of PZA among first-line anti-
TB drugs, it is important to identify PZA resistance in
clinical practice, especially in dealing with MDRTB
cases. The purpose of the present study was to identify
the characteristics of pncA mutations in clinical
MDRTB isolates, and evaluate the effectiveness of pncA
gene analysis in identifying PZA-susceptible isolates.
The impact of genotyping in PZA resistance was also
investigated.
Methods
Mycobacterial isolates
This study was conducted in six hospitals in Taiwan,
including five referral medical centers and one regional
hospital that specialize in pulmonary diseases. MDRTB
clinical isolates were collected from newly diagnosed
tuberculosis patients from January 2007 to December
2009. The demographic profiles and clinical characteris-
tics of the patients were obtained from medical records,
and the chest radiograms were interpreted by the in-
charge doctors of each hospital. The institutional review
boards of all six hospitals approved the study and
informed consent was obtained from each patient before
enrollment.
Drug susceptibility testing (DST) and PZase assay
The drug susceptibilities of isoniazid and rifampicin
were performed by the proportion method and their cri-
tical concentrations for resistance were as follows: iso-
niazid, 0.2 μg/ml and 1.0 μg/ml; rifampicin, 1.0 μg/ml
and 5.0 μg/ml (20). MDRTB isolates were defined as
those resistant to low drug concentration levels in both
isoniazid and rifampicin. The susceptibility of PZA was
assessed by the non-radiometric BACTEC Mycobacteria
Growth Indicator Tube (MGIT) 960 method (BD Bios-
ciences, Sparks, MD, USA). The recommended critical
concentration of 100 μg/ml PZA was used to discrimi-
nate between PZA-susceptible and PZA-resistant iso-
lates. The PZase activity test was performed according
to Wayne’s procedure (21).
DNA extraction, pncA gene sequencing
Genomic DNA was extracted from Middlebrook 7H11
cultures as described previously (22). Entire pncA genes
and 82 bp of an upstream putative regulatory sequence
were amplified by polymerase chain reaction (PCR) with
forward (P1) and reverse (P6) primers as described pre-
viously (23). Briefly, the PCR mixture (100 μL) con-
tained ~1 ng of DNA template, final concentrations of
1.0 μM of each set of primers, 200 μM deoxynucleoside
triphosphate (dATP, dCTP, dGTP and dTTP; Pharma-
cia, Uppsala, Sweden) and 10 μL Taq buffer and 5.0 U/
μL Taq polymerase (Gibco-Bethesda Research Labora-
tories). Amplification was performed for 40 cycles (1
min at 94°C, 1 min at 56°C and 1 min at 72°C) by a
GeneAmp PCR system 9700 thermocycler (Perkin
Elmer, Applied Biosystems, CA). To determine the pncA
sequence, PCR products were purified with a QIAquick
PCR purification kit (Qiagen GmbH, Hilden, Germany).
The PCR products were directly sequenced using an
ABI 377 automatic DNA sequencer (Perkin Elmer,
Applied Biosystems, CA).
Genotyping
All clinical isolates were genotyped by a commercial
spoligotyping kit (Isogen Bioscience B.V., Maarssen,
Netherlands). The “Beijing strain” was defined as dele-
tion from spacer 1 to spacer 34 in the direct repeat
region and the presence of (at least 3) spacers 35-43.
Data analysis
Comparisons of demographic and clinical characteristics
were done using the chi-square test or Fisher’se x a c t
test for categorical variables, and the two-tailed indepen-
dent t test for continuous variables. Binary logistic
regression analysis was performed to determine the
independent variables, and odds ratios with their 95%
confidence intervals were presented. The sensitivity, spe-
cificity, positive predictive value (PPV) and negative pre-
dictive value (NPV) of the pncA gene mutations and
PZase activity test were calculated according to the PZA
susceptibility results. Significance was defined as p <
0.05 (two-tailed). Statistical analysis was performed
using a statistical software package (SPSS version 17.0,
SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
During the study period, a total of 66 MDRTB isolates
were collected from newly diagnosed tuberculosis
patients in six hospitals in Taiwan. Among these
MDRTB isolates, 36 (54.5%) were resistant to PZA and
30 (45.5%) were susceptible to PZA according to the
DST results assessed by the MGIT 960 method. The
demographic data of these patients are shown in Table
1. MDRTB isolates with concomitant PZA resistance
were more likely to be sputum smear negative at the
diagnosis of tuberculosis (52.8% vs. 26.7%, p = 0.032),
and more likely to be associated with ethambutol (58.3%
vs. 33.3%, p = 0.043) and streptomycin resistance (66.7%
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including age, gender, previous anti-TB treatment,
smear positivity, and the presence of cavities in radio-
graphs, were comparable between patients infected with
PZA-resistant or susceptible MDRTB isolates. Of these
MDRTB isolates, 37 (56.1%) were Beijing and 29 (43.9%)
non-Beijing strains. The proportion of PZA-resistant
isolates was similar between the Beijing and non-Beijing
strains.
PZA susceptibility results and mutations in the pncA gene
The mutations in the pncA gene and the correlation
with PZA susceptibility testing are shown in Table 2. Of
66 clinical MDRTB isolates, 36 were wild type and the
other 30 were associated with at least one pncA gene
mutation. Among these 30 isolates, we found 36 unique
mutations out of a total of 39 different mutations. The
majority of these were point mutations that resulted in
nucleotide substitutions (37/39, 94.9%). There was one
deletion (1/39, 2.6%) and one insertion (1/39, 2.6%). In
addition, three isolates were identified to possess more
t h a no n es i t eo fpncA mutation in a single isolate, and
all of these isolates were resistant to PZA. The muta-
tions were scattered along the pncA gene and no highly
conservative region could be identified. Seven isolates
with the wild-type pncA gene were found to be resistant
to PZA. Meanwhile, one isolate which was susceptible
to PZA had a pncA gene mutation (A98C, Asp(33)
®Ala).
Genotyping and PZA susceptibility results
The comparison of PZA susceptibility testing and pncA
mutations and the impact of genotyping are shown in
Table 3. Among 36 isolates with PZA resistance, 29
were documented with pncA gene mutations. Among 30
isolates which were susceptible to PZA, 29 were asso-
ciated with the wild type pncA gene. Overall, the sensi-
tivity and specificity of pncA gene mutations in
predicting PZA resistance were 80.6% and 96.7%,
respectively. In isolates belonging to Beijing genotypes
(37 isolates), the sensitivity and specificity were 76.2%
and 93.8%, respectively. In non-Beijing strains (29 iso-
lates), the sensitivity and specificity were 86.7% and
100%, respectively.
The concordance of PZA susceptibility testing and
PZase activity and the impact of genotyping are shown
in Table 4. Among 36 PZA-resistant isolates, 21 had no
detectable PZase activity as judged by Wayne’sm e t h o d .
In 30 PZA-sensitive isolates, 28 had positive PZase
activity. The overall sensitivity and specificity of PZase
activity testing in predicting PZA resistance were 58.3%
and 93.3%, respectively. In 37 Beijing strain isolates, the
sensitivity and specificity were 66.7% and 93.8%, respec-
tively. In 29 non-Beijing strain isolates, the sensitivity
and specificity were 46.7% and 92.9%, respectively.
Discussion
PZA is an important and effective first-line anti-TB drug
both in MDRTB and fully susceptible isolates. However,
traditional susceptibility testing of PZA is of limited
value and not routinely performed. Detection of pncA
gene mutations may provide rapid and reliable informa-
tion about PZA susceptibility profiles. In our analysis,
more than half of the MDRTB isolates were also resis-
tant to PZA. No clinical characteristics have a good cor-
relation with PZA resistance, except for concomitant
resistance to other first-line anti-TB agents. The analysis
of pncA gene mutations is a test of high specificity and
moderate sensitivity in predicting PZA resistance. The
correlation between pncA gene mutations and PZA
resistance is slightly better in non-Beijing strains as
compared with Beijing strains. The present study sug-
gests that pncA gene analysis is useful in identifying
Table 1 Demographic data of the multidrug-resistant
tuberculosis patients with or without pyrazinamide (PZA)
resistance
a
PZA susceptibility test P
value
Resistant, n =
36
Susceptible, n =
30
Age (MD) 58.3 (21.0) 57.8 (17.8) 0.91
Gender
Male 25 (69.4%) 24 (80%) 0.33
Female 11 (30.6%) 6 (20%)
Previous anti-TB treatment
Yes 11 (30.6%) 10 (33.3%) 0.81
No 25 (69.4%) 20 (66.7%)
Sputum smear
Positive 17 (47.2%) 22 (73.3%) 0.032
Negative 19 (52.8%) 8 (26.7%)
Disease site
Pulmonary TB 35 (97.2%) 28 (93.3%) 0.45
Extrapulmonary TB 1 (2.8%) 2 (6.7%)
Presence of cavity in
radiogram
Yes 8 (22.2%) 12 (40%) 0.12
No 28 (77.8%) 18 (60%)
Ethambutol resistance
Yes 21 (58.3%) 10 (33.3%) 0.043
No 15 (41.7%) 20 (66.7%)
Streptomycin resistance
Yes 24 (66.7%) 11 (36.7%) 0.015
No 12 (33.3%) 19 (63.3%)
Genotyping
Beijing strain 21 (58.3%) 16 (53.3%) 0.68
Non-Beijing strain 15 (41.7%) 14 (46.7%)
aData are presented as n(%) unless otherwise stated.
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in non-Beijing strains. However, the presence of wild
type pncA genes in PZA-resistant isolates also suggests
that mechanisms other than pncA gene mutations lead-
ing to PZA resistance may exist, and this deserves
further exploration.
Classified as a first-line oral anti-TB agent, PZA is
widely used in the intensive phase of anti-TB treatment
and plays a pivotal role in the treatment regimen of
MDRTB and extensively drug-resistant tuberculosis
(XDRTB) disease. Unfortunately, concomitant resistance
to other first-line anti-TB drugs, including PZA, is not
uncommon in MDRTB and XDRTB isolates. Due to dif-
ficulties in performing PZA susceptibility tests and the
unreliable results of the traditional method, information
about PZA resistance in MDRTB isolates is not routi-
nely obtained in clinical settings. Recent studies from
South Africa and Thailand reported a PZA resistance
Table 2 pncA gene mutation analysis, PZase activity test, and spligotyping of the MDRTB isolates
Mutation
site
No. of
isolates
Nucleotide
substitution
Amino acid
change
PZA
susceptibility
PZase
activity
Spoligotyping
71 G ®T Ala(3)®Ser Resistant + Beijing
68 1 G®C Gly(23)®Ala Resistant + H3
83 1 C®T Ala(28)®Val Resistant + T1
98 1 A®C Asp(33)®Ala Sensitive + Beijing
134 1 T®G Val(45)®Gly Resistant - Beijing
135 1 T®C Val(45)®Ala Resistant - Orphan strain
161 1 C®T Pro(54)®Leu Resistant + Orphan strain
165 1
a T®A Gly(55)®Gly Resistant - Beijing
166 1
a G®T Gly(55)®Gly Resistant - Beijing
167 1
a A®G Asp(56)®Cys Resistant - Beijing
170 1
a A®C His(57)®Pro Resistant - Beijing
171 1, 1
a C®T His(57)®Pro Resistant 1+, 1- Beijing
174 1
a C®A Phe(58)®Leu Resistant - Beijing
168 1 Ins C Frameshift Resistant - Beijing
185 1 C®A Pro(62)®Gln Resistant + Beijing
211 1 C®T His(71)®Tyr Resistant - Beijing
225 1 A®G Thr(76)®Ala Resistant - Orphan strain
233 1 G®T Gly(78)®Gly Resistant - Beijing
248 1 C®G Pro(83)®Arg Resistant + Orphan strain
254 1 T®C Leu(85)®Pro Resistant - Beijing
290 1 G®A Gly(97)®Asp Resistant - Beijing
298 1
b A®G Thr(100)®Ala Resistant - Orphan strain
442 1
b C®T Arg(148)®Cys Resistant - Orphan strain
308 1 A®G Tyr(103)®Cys Resistant - Beijing
207-209 1
c del ACC - Resistant - Orphan strain
319 1
c G®T Glu(107)®Glu Resistant - Orphan strain
403 1
c A®G Thr(135)®Ala Resistant - Orphan strain
461 1
c G®C Arg(154)®Thr Resistant - Orphan strain
335 2 A®T Asn(112)®Tyr Resistant 1+, 1- Beijing, T2
364 1 C®T Gln(122)®Gln Resistant - Beijing
394 1 G®A Gly(132)®Ser Resistant + Orphan strain
395 1 G®A Gly(132)®Asp Resistant - Orphan strain
401 1 C®T Ala(134)®Val Resistant - Beijing
416 2 T®C Val(139)®Ala Resistant 1+, 1- Beijing, U
529 1 A®C Thr(177)®Pro Resistant + Orphan strain
551 1 G®A Csy(184)®Tyr Resistant - Beijing
- 7 WT WT Resistant 4+, 3- Beijing, Orphan strain
- 29 WT WT Sensitive 27+, 2- Beijing, H3, Orphan strain, T1, T2-
T3
a, b, c Multiple mutations within one isolate
WT: wild type
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with these reports, the PZA resistance rate was 54.5% in
the present study by the BACTEC MGIT 960 method.
The underlying mechanism leading to the high PZA
resistance rate in MDRTB isolates remains to be identi-
fied. However, an increased incidence of previous PZA
exposure in these isolates is a possible cause (26).
Assuming that approximately half of MDRTB isolates
are resistant to PZA, then nearly half of them are PZA-
susceptible. If we can identify the PZA-susceptible
MDRTB isolates timely and accurately, it would be pos-
sible to add PZA to the combination of anti-TB drugs
for MDRTB patients.
The early identification of drug susceptibility by drug
resistance gene analysis has been widely used for first-
line anti-TB drugs in recent years, especially rifampicin
and isoniazid (27). The PZase enzyme, encoded by the
pncA gene, plays a vital role in the bactericidal effect of
PZA against MTB isolates (11-13). Theoretically, pncA
gene analysis should enable clinicians to identify PZA
resistance early. However, the correlation between pncA
gene mutations and PZA susceptibility varies among
previous studies (14-17). As compared with the BAC-
TEC MGIT 960 method, the overall sensitivity and spe-
cificity of pncA gene analysis in the present study were
80.6% and 96.7%, respectively, which is comparable with
previous reports (17, 24). The high specificity suggests
that pncA gene analysis is an ideal method to identify
PZA-resistant MDRTB isolates. Meanwhile, the rela-
tively lower sensitivity means that false negative results
are possible and implies that mechanisms other than
pncA mutations are involved in PZA resistance.
Although pncA gene analysis is a rapid test with a high
positive predictive value, it cannot completely replace
the phenotypic susceptibility testing of PZA.
We found a high diversity of pncA gene mutations
without major hot spots in the MDRTB isolates. Among
36 PZA-resistant MDRTB isolates, 38 different muta-
tions scattered along the whole pncA gene were identi-
fied out of 29 isolates. Meanwhile, one mutation at
nucleotide 98(A®C) was found in one isolate among 30
PZA-susceptible MDRTB isolates. No clustered isolates
were found to share identical pncA gene mutations and
spoligotyping in our analysis. Our findings of scattered
mutations support similar observations in previous stu-
dies (16, 24). The high diversity of pncA gene mutations
could also be used as a supplement to current genotyp-
ing methods in epidemiological investigations.
In the present study, we also evaluated PZase activities
by Wayne’s test, which is based on the detection of
Table 3 Concordance of pncA gene analysis and PZA susceptibility testing by the BACTEC MGIT 960 method
pncA gene mutation Sensitivity (%) Specificity (%) PPV (%) NPV (%)
PZA susceptibility Yes
Overall, n = 66 80.6 96.7 96.7 80.6
Resistance 29 7
Susceptible 1 29
Beijing strain, n = 37 76.2 93.8 94.1 75
Resistance 16 5
Susceptible 1 15
Non-Beijing strain, n = 29 86.7 100 100 87.5
Resistance 13 2
Susceptible 0 14
PZA, pyrazinamide; PPV, positive predictive value; NPV, negative predictive value.
Table 4 Concordance of PZase activity and PZA susceptibility testing by the BACTEC MGIT 960 method
PZase activity Sensitivity (%) Specificity (%) PPV (%) NPV (%)
PZA susceptibility Negative
Overall, n = 66 58.3 93.3 91.3 65.1
Resistance 21 15
Susceptible 2 28
Beijing strain, n = 37 66.7 93.8 93.3 68.2
Resistance 14 7
Susceptible 1 15
Non-Beijing strain, n = 29 46.7 92.9 87.5 61.9
Resistance 7 8
Susceptible 1 13
PZase, pyrazinamidase; PZA, pyrazinamide; PPV, positive predictive value; NPV, negative predictive value.
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susceptibility was comparable with that of pncA gene
analysis, but the sensitivity was much lower. Moreover,
a significant proportion of isolates with pncA gene
mutations possessed detectable PZase activity (14/30,
46.7%). According to previous reports, the sensitivity of
the PZase assay ranged from 79% to 96% and the speci-
ficity was generally above 95% (28, 29). The cause of the
remarkable discordance between the PZase assay test,
pncA gene analysis, and PZA susceptibility in the pre-
sent study could not be readily clarified in the study
design. The geographic differences in MDRTB isolates
may have contributed to the differences between our
findings and previous reports. It is possible that some
pncA gene mutations may lead to a reduction, but not
loss, of PZase activity that can still be detected by
Wayne’s test. Although the PZase activity is not totally
lost in these isolates, it results in phenotypical resistance
to PZA. Unlike previous studies that enrolled both
MDRTB and non-MDRTB isolates, only MDRTB iso-
lates were included for analysis in the present study.
The different composition of MTB isolates, including
various genotypes and drug susceptibility profiles, may
affect the predictive value of PZase activity testing and
causes of the discordant results.
The difference of PZA susceptibility and pncA gene
mutations among various genotypes of MTB isolates has
rarely been evaluated before. The Beijing strain is the
dominant strain in Eastern Europe and Southeastern
Asia, including Taiwan (30). Differences in clinical pre-
sentations and treatment outcomes have been reported,
although with some controversy among various geogra-
phical areas (3, 31). In the present study, we compared
the correlation of pncA gene analysis, PZase activity,
and PZA susceptibility between Beijing and non-Beijing
strains. We demonstrated that the Beijing strain had a
slightly lower sensitivity in pncA gene analysis, but
much higher sensitivity in PZase activity test, as com-
pared with non-Beijing strains. By comparison, the spe-
cificity was similar between Beijing and non-Beijing
strains in both pncA gene analysis and PZase activity
tests. No specific mutation was found in Beijing or non-
Beijing genotype isolates. Our data demonstrated differ-
ent genetic and phenotypic characteristics of Beijing and
non-Beijing strains in PZA resistance. The differences
between Beijing and non-Beijing strains in PZA suscept-
ibility warrant further verification with a larger sample
size, and the underlying mechanism remains to be
clarified.
In the present study, we found that MDRTB patient
with concomitant PZA resistance were more likely to be
sputum smear negative. The cause of significant correla-
tion between PZA susceptibility and sputum smear
r e s u l t sc a n n o tb ee a s i l yi d e n t i f i e di nt h es t u d yd e s i g n .A
recent study showed that exposure of lowly active MTB
bacilli to anti-TB agents led to the emergence of resis-
tant mutants and it required higher drug concentrations
to eliminate metabolic inactive mycobacteria (32).
Therefore, the MDRTB isolates with PZA resistance are
probably less metabolic active which may lead to the
lower sputum smear positive rate. Further in-vivo and
in-vitro studies will be needed to verify the issue and
elucidate the underlying mechanism.
Our study has several limitations. Only MDRTB iso-
lates were included for analysis and the predictive
value of pncA gene analysis in non-MDRTB isolates
could not be evaluated in the present study. We did
not evaluate the mutation of other important drug
resistant gene, such as rpoB, inhA,a n dkatG,i nt h e s e
isolates. The relatively small case numbers may also
lead to a lower power of our analysis. More impor-
tantly, this study was performed in a TB endemic area
with a predominance of the Beijing strain. It remains
to be determined if our findings can be applied to
areas with a lower TB incidence or without predomi-
nance of the Beijing strain.
Conclusions
Our study demonstrated that the PZA resistant rate in
MDRTB isolates was high, and the majority of the PZA-
susceptible isolates presented with wild type pncA genes.
Analysis of pncA g e n e si sat e s to fh i g hs p e c i f i c i t yi n
predicting PZA resistance, enabling clinicians to add
PZA timely and accurately to treatment regimens for
MDRTB patients. The concordance between pncA gene
analysis and PZA resistance was better in non-Beijing as
compared with Beijing strains, suggesting that pncA
gene analysis is more suitable for MDRTB isolates
belonging to non-Beijing strains.
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